ATMP Firms Call For Streamlined EU Trial Approvals To Boost Competitiveness
Bluebird Bio & ARM Are Cautiously Optimistic Of Change
Gene therapy developer bluebird bio and the Alliance for Regenerative Medicine say that Europe is losing its edge in advanced therapy clinical trials. But they believe that recommendations made in a new report from ARM could help kickstart moves to streamline trial approvals for cell and gene therapies.
You may also be interested in...
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.